A treatment algorithm for ischemic cardiomyopathy

Raffaele De Caterina1, Riccardo Liga1

  • 1Cardiology Division, Pisa University Hospital and Chair of Cardiology, University of Pisa, Pisa, Italy.

Vascular Pharmacology
|January 5, 2024
PubMed

Insights

Percutaneous coronary intervention (PCI) may be futile for ischemic cardiomyopathy. Coronary artery bypass grafting (CABG) may offer long-term prognostic improvement, guiding patient selection for revascularization.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Interventional Cardiology

Background:

  • Recent studies question the efficacy of percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) versus OMT alone for ischemic cardiomyopathy.
  • Older trials suggest coronary artery bypass grafting (CABG) may provide long-term prognostic benefits in similar patient populations.

Discussion:

  • This manuscript reviews current evidence on managing ischemic cardiomyopathy.
  • It emphasizes the need for careful patient selection based on clinical presentation, imaging, and surgical risk.
  • The focus is on providing practical guidance for treatment decisions.

Key Insights:

  • PCI may not be beneficial for myocardial revascularization in ischemic cardiomyopathy.
  • CABG might offer a better long-term outcome compared to PCI.
  • Triage decisions require a comprehensive assessment of individual patient factors.

Outlook:

  • Further research is needed to clarify the optimal revascularization strategy for ischemic cardiomyopathy.
  • Developing refined patient selection criteria is crucial for improving treatment outcomes.
  • This work aims to guide clinicians in making informed treatment choices for these complex patients.